Logo image of AVTX

AVALO THERAPEUTICS INC (AVTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AVTX - US05338F3064 - Common Stock

18.37 USD
-0.54 (-2.86%)
Last: 12/26/2025, 8:00:00 PM
18.7 USD
+0.33 (+1.8%)
After Hours: 12/26/2025, 8:00:00 PM
Fundamental Rating

4

AVTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVTX as it has an excellent financial health rating, but there are worries on the profitability. AVTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AVTX had negative earnings in the past year.
In the past year AVTX has reported a negative cash flow from operations.
AVTX had negative earnings in each of the past 5 years.
AVTX had a negative operating cash flow in each of the past 5 years.
AVTX Yearly Net Income VS EBIT VS OCF VS FCFAVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of AVTX (-79.77%) is worse than 68.11% of its industry peers.
AVTX has a Return On Equity (-109.00%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.77%
ROE -109%
ROIC N/A
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVTX Yearly ROA, ROE, ROICAVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

Looking at the Gross Margin, with a value of 420.31%, AVTX belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
In the last couple of years the Gross Margin of AVTX has grown nicely.
The Profit Margin and Operating Margin are not available for AVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 420.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
AVTX Yearly Profit, Operating, Gross MarginsAVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

AVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AVTX has more shares outstanding
AVTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVTX Yearly Shares OutstandingAVTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
AVTX Yearly Total Debt VS Total AssetsAVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 0.35, we must say that AVTX is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.35, AVTX is doing good in the industry, outperforming 60.94% of the companies in the same industry.
There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.35
ROIC/WACCN/A
WACC8.78%
AVTX Yearly LT Debt VS Equity VS FCFAVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

AVTX has a Current Ratio of 14.28. This indicates that AVTX is financially healthy and has no problem in meeting its short term obligations.
AVTX has a Current ratio of 14.28. This is amongst the best in the industry. AVTX outperforms 90.75% of its industry peers.
A Quick Ratio of 14.28 indicates that AVTX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 14.28, AVTX belongs to the best of the industry, outperforming 90.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.28
Quick Ratio 14.28
AVTX Yearly Current Assets VS Current LiabilitesAVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.12% over the past year.
Looking at the last year, AVTX shows a very negative growth in Revenue. The Revenue has decreased by -76.59% in the last year.
The Revenue for AVTX have been decreasing by -42.05% on average. This is quite bad
EPS 1Y (TTM)95.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.2%
Revenue 1Y (TTM)-76.59%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 14.64% on average over the next years. This is quite good.
Based on estimates for the next years, AVTX will show a very strong growth in Revenue. The Revenue will grow by 111.61% on average per year.
EPS Next Y96.32%
EPS Next 2Y40.34%
EPS Next 3Y25.47%
EPS Next 5Y14.64%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y111.61%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AVTX Yearly Revenue VS EstimatesAVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2029 2030 2031 2032 50M 100M 150M 200M
AVTX Yearly EPS VS EstimatesAVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2K -4K -6K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVTX Price Earnings VS Forward Price EarningsAVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVTX Per share dataAVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as AVTX's earnings are expected to grow with 25.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.34%
EPS Next 3Y25.47%

More info and screens

0

5. Dividend

5.1 Amount

AVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AVALO THERAPEUTICS INC

NASDAQ:AVTX (12/26/2025, 8:00:00 PM)

After market: 18.7 +0.33 (+1.8%)

18.37

-0.54 (-2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners75.73%
Inst Owner Change97.37%
Ins Owners3.45%
Ins Owner Change-3.01%
Market Cap333.05M
Revenue(TTM)192.00K
Net Income(TTM)-99.79M
Analysts86.67
Price Target34.39 (87.21%)
Short Float %11.65%
Short Ratio5.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-31.71%
Min EPS beat(2)-33.98%
Max EPS beat(2)-29.44%
EPS beat(4)1
Avg EPS beat(4)-485.44%
Min EPS beat(4)-1889.97%
Max EPS beat(4)11.62%
EPS beat(8)1
Avg EPS beat(8)-1992.39%
EPS beat(12)4
Avg EPS beat(12)-1320.52%
EPS beat(16)7
Avg EPS beat(16)-983.66%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.26%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)13.88%
EPS NY rev (1m)-0.64%
EPS NY rev (3m)-0.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1734.63
P/FCF N/A
P/OCF N/A
P/B 3.64
P/tB 4.11
EV/EBITDA N/A
EPS(TTM)-13.31
EYN/A
EPS(NY)-5
Fwd EYN/A
FCF(TTM)-2.88
FCFYN/A
OCF(TTM)-2.88
OCFYN/A
SpS0.01
BVpS5.05
TBVpS4.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.77%
ROE -109%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 420.31%
FCFM N/A
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.28
Quick Ratio 14.28
Altman-Z 0.35
F-Score4
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)52.94%
Cap/Depr(5y)33.74%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.2%
EPS Next Y96.32%
EPS Next 2Y40.34%
EPS Next 3Y25.47%
EPS Next 5Y14.64%
Revenue 1Y (TTM)-76.59%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y111.61%
EBIT growth 1Y-82.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.93%
OCF growth 3YN/A
OCF growth 5YN/A

AVALO THERAPEUTICS INC / AVTX FAQ

Can you provide the ChartMill fundamental rating for AVALO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to AVTX.


Can you provide the valuation status for AVALO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to AVALO THERAPEUTICS INC (AVTX). This can be considered as Overvalued.


How profitable is AVALO THERAPEUTICS INC (AVTX) stock?

AVALO THERAPEUTICS INC (AVTX) has a profitability rating of 2 / 10.


What is the earnings growth outlook for AVALO THERAPEUTICS INC?

The Earnings per Share (EPS) of AVALO THERAPEUTICS INC (AVTX) is expected to grow by 96.32% in the next year.